Chlamydia pneumoniae - Atherosclerosis link: A sound concept in search for clinical relevance

Circulation

Volumn 106, Issue 19, 2002, Pages 2414-2416

  Neumann, Franz Josef ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Arteriosclerosis; Editorials; Immune system; Infection; Thrombosis

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; BACTERIAL DNA; HEAT SHOCK PROTEIN 60; PLACEBO; PRAVASTATIN; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMON CAROTID ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; CORONARY STENT; DISEASE ASSOCIATION; EDITORIAL; FOLLOW UP; HEART INFARCTION; HUMAN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ARTERIOSCLEROSIS; AZITHROMYCIN; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FOLLOW-UP STUDIES; HUMANS; MORBIDITY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; ROXITHROMYCIN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 0037027465     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000040403.57597.48     Document Type: Editorial

References (22)

1. Gupta S, Leatham EW. Carrington D. et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
2. Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet. 1997;350:404-407.
3. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002;105:1555-1560.
4. Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial. Circulation. 2002;105:2646-2652.
5. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-986.
6. Danesh J, Whincup P, Lewington S, et al, Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:371-375.
7. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996:27:1555-1561.
8. Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827-832.
9. Mosorin M, Surcel HM, Laurila A, et al. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol. 2000;20:1061-1067.
10. Coombes BK, Mahony JB. cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection. Infect Immun. 2001;69:1420-1427.
11. May AM, Massberg S. Redecke V, et al. Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, non-atherosclerotic mice. Circulation. In press. Abstract.
12. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
13. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest. 1999;103:747-753.
14. Parchure N, Zouridakis EG. Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation. 2002;105: 1298-1303.
15. Sander D, Winbeck K, Klingelhöfer J, et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation. 2002:106:2428-2433.
16. Sander D, Winbeck K, Klingelhofer J, et al. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. Circulation. 2001;103:1390-1395.
17. Stemme S. Faber B, Holm J. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995;92:3893-3897.
18. Klouche M, May AE, Hemmes M, et al. Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers. Arterioscler Thromb Vasc Biol. 1999;19:784-793.
19. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002; 105:15-21.
20. Neumann FJ, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial. Lancet. 2001;357:2085-2089.
21. Xu Q, Kiechl S, Mayr M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: Clinical significance determined in a follow-up study. Circulation. 1999;100:1169-1174.
22. Huittinen T, Leinonen M, Tenkanen L, et al. Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk. Arterioscler Thromb Vasc Biol. 2002;22:431-437.